| Methods and compositions for treatment of epileptic disorders |
2023-8-17 |
2023-9-07 |
|
| Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and … |
2023-7-05 |
2023-9-01 |
|
| Methods and compositions for treatment of epileptic disorders |
2023-5-30 |
2023-9-21 |
|
| Methods of increasing tonic depression and treating secondary insomnia |
2023-5-30 |
2023-9-05 |
|
| Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
2023-5-19 |
2023-9-14 |
|
| How to treat developmental disorders with gaboxadol |
2023-5-16 |
2023-7-26 |
|
| Methods and compositions for treatment of epileptic disorders |
2023-4-06 |
2023-9-21 |
|
| shRNA TARGETING UBE3A-ATS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN … |
2023-3-07 |
2023-9-14 |
|
| shRNA TARGETING SNORD115 LOCATIONS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN … |
2023-3-07 |
2023-9-14 |
|
| Treatment of depressive disorders |
2023-1-25 |
2023-5-02 |
|
| Methods of treating seizure disorders and Prader-Willi syndrome |
2022-11-11 |
2023-2-21 |
|
| Use of gaboxadol in the treatment of tinnitus |
2022-10-11 |
2023-1-24 |
|
| Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
2022-6-14 |
2022-8-01 |
|
| Use of gaboxadol in the treatment of substance use disorders |
2022-4-19 |
2022-8-04 |
|
| Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
2022-1-06 |
2022-3-01 |
|
| Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders |
2021-12-21 |
2022-4-14 |
|
| Methods of treating developmental disorders and/or seizure disorders with … |
2021-10-26 |
2021-11-25 |
|
| Recombinant adeno-associated vectors |
2021-8-12 |
2021-12-02 |
|
| Methods of treating attention deficit hyperactivity disorder |
2021-6-02 |
2021-9-16 |
|
| Methods of treating developmental disorders using pipradrol |
2021-4-26 |
2021-6-30 |
|
| Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
2021-3-15 |
2021-4-29 |
|
| Use of gaboxadol in the treatment of gastrointestinal tract disorders and … |
2021-2-14 |
2021-4-29 |
|
| Use of mir-92a or mir-145 in the treatment of angelman syndrome |
2020-12-13 |
2021-1-31 |
|
| Use of mir101 or mir128 in the treatment of seizure disorders |
2020-11-17 |
2021-4-01 |
|
| Use of gaboxadol in the treatment of diabetes and related conditions |
2020-10-08 |
2021-2-04 |
|
| Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid … |
2020-9-24 |
2020-11-30 |
|
| Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid … |
2020-7-26 |
2020-9-30 |
|
| Use of hm4di in the treatment of seizure disorders |
2020-6-14 |
2020-7-30 |
|
| Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid … |
2020-4-17 |
2020-8-06 |
|
| Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid … |
2020-4-17 |
2023-10-03 |
2023-10-03 |
| Use of gaboxadol in the treatment of narcolepsy |
2020-3-25 |
2020-7-16 |
|
| Use of designer receptors exclusively activated by designer drugs in the … |
2019-9-12 |
2019-11-28 |
|
| Methods of treating developmental disorders and/or seizure disorders with … |
2019-8-13 |
2020-1-02 |
|
| Methods of treating seizure disorders |
2019-8-05 |
2019-9-26 |
|
| Use of phenylethylidenehydrazine to treat seizure disorders, developmental … |
2019-7-18 |
2020-1-23 |
|
| Methods of treating developmental syndromes with pde10a inhibitors |
2019-2-15 |
2019-8-15 |
|
| Methods of treating behavioral syndromes using pipradrol |
2018-11-13 |
2018-12-31 |
|
| Methods of treating developmental disorders with biguanides |
2018-10-11 |
2019-10-01 |
2019-10-01 |
| Treatment of developmental syndromes |
2018-6-28 |
2019-1-03 |
|
| Treatment of developmental disorders with imidazolone derivatives |
2018-6-01 |
2018-12-06 |
|
| Methods of treating developmental encephalopathies |
2018-4-12 |
2020-9-08 |
2020-9-08 |
| Sedation methods and parenteral formulation for use during critical care … |
2018-3-09 |
2018-5-31 |
|
| Methods of treating prader-willi syndrome |
2017-8-22 |
2017-12-07 |
|
| Methods of sedation during critical care treatment |
2017-6-27 |
2017-10-19 |
|
| Methods of treating developmental disorders using gaboxadol |
2017-6-07 |
2017-11-09 |
|
| Formulations of gaboxadol for treatment of angelman syndrome, fragile x … |
2017-6-07 |
2017-12-07 |
|
| Treatment of cognitive impairment |
2016-10-13 |
2017-5-04 |
|
| PARENTERAL SEDATION METHODS TO USE DURING INTENSIVE CARE TREATMENT |
2016-8-10 |
2017-10-25 |
|
| Methods of sedation and parenteral formulation for use during critical care … |
2016-8-02 |
2017-2-16 |
|
| METHODS OF TREATMENT OF DISORDERS OF DEVELOPMENT WITH GABOXADOL |
2016-7-15 |
2017-9-27 |
|